Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. - Wikidata - wikimedia - TriplyDB

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

http://www.wikidata.org/entity/Q34649706

about

Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease Initial medication in patients of newly diagnosed Parkinson's disease in Taiwan An update on the diagnosis and treatment of Parkinson disease A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.Non-human primate FOG develops with advanced parkinsonism induced by MPTP Treatment.Exenatide and the treatment of patients with Parkinson's disease Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.Paired-pulse inhibition in the auditory cortex in Parkinson's disease and its dependence on clinical characteristics of the patients.Review: management of Parkinson's disease.Validation of an instrument to measure older adults' expectations regarding movement (ERM).Seniors with Parkinson's disease: initial medical treatment.Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis.Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients.Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study Parkinson's disease severity and use of dopaminergic medications.Present and future drug treatment for Parkinson's disease.Medication responsiveness of motor symptoms in a population-based study of Parkinson disease.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Patient considerations in early management of Parkinson's disease: focus on extended-release pramipexole Health-related quality of life as an outcome variable in Parkinson's disease.Dyskinesias and treatment with pramipexole in patients with Parkinson's disease.Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease.Clinical aspects and management of levodopa-induced dyskinesia.A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis.Patient perspectives on Parkinson's disease therapy in Japan and the United States: results of two patient surveys.Combination therapies: The next logical Step for the treatment of synucleinopathies?National Trends of Antiparkinsonism Treatment in Taiwan: 2004-2011.Treatment of Parkinson's disease in the advanced stage.Update on the use of pramipexole in the treatment of Parkinson's disease.Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson's Disease Patients: A Meta-Analysis of Randomized Controlled Trials Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.Pharmacotherapy for Parkinson's disease.Parkinson's disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion.Potential Role of Caffeine in the Treatment of Parkinson's Disease.Current status of symptomatic medical therapy in Parkinson's disease

P2860

Q24646422-78A8CA78-C8FB-48D4-BDD7-01BF6142656E Q24647141-691862A5-E4E4-46B0-982F-7E9E2C84FF8E Q26748711-E0FFBD68-E461-4A74-A95D-319BAFB45D04 Q28542989-6EFCBA28-D34B-4EB9-9A94-0F7027ACBADA Q30243899-F03CB5AF-952B-4D4F-ABB1-F9E1A5C979C1 Q30407150-2A5A1E8C-9475-45D0-B800-9455F22BDC5E Q30417007-754AE110-5607-4F7C-88F1-9D16CBE0C8AF Q30536650-7391E498-6973-4567-B197-692DFA25A5C0 Q30540208-EE683E8C-4FB2-46FA-B13E-F6F1D77D07AE Q33260250-EA380C0A-895B-4740-9589-F10F9301CBB4 Q33989482-AA49D816-7149-4934-9D24-E729844F336C Q34027880-16BD3A7E-2DD7-4B59-BF3A-9DB63942C5BA Q34261531-7A0A885E-BD4F-47C3-9C2D-94D4236DD350 Q34332812-199DAB0B-13BA-47BD-B66C-463001DA81D6 Q34399483-8FFD0A67-5B50-4765-B223-720F8EC2E130 Q34508143-922D9A61-6F35-4411-ABC0-85519ABF52B5 Q34921068-8640EE84-0D26-44B2-A7E4-37E601B982B7 Q35006707-BF986EDA-BEB7-40A8-AC37-9D47A95671A3 Q35016008-63C1E457-5A83-4D52-85E8-610BB3A46051 Q35122279-73C7EBEE-ED76-4C15-84A2-09AEB1ADD389 Q35484805-C807D585-18E3-4E4B-9062-65CBFFA9018D Q35609028-BEA74596-52FC-4F26-B40F-76DE60A3DA6F Q35614156-021F8E28-C42E-4DBE-B589-84F40F9B1C99 Q35716858-F79C5CC8-D77D-4C89-8FF2-28E8BF16E17D Q35825918-9B915FC9-299B-40BB-82E3-6C4BA213A5ED Q35837892-B437A619-6728-4B11-BDBA-3B9102CA1B2A Q35885133-132DA2D0-8EBA-43F7-ACC3-7F3D5FF8195D Q36022700-950708A9-B0B2-4CA6-A7B1-571FBEB8DF2F Q36227451-CB3701CF-987F-4F31-ABD9-76859B0BE99C Q36429865-F16B2931-BEE2-4C2C-8B26-C9AE4AD1B3E9 Q36563062-98E732B5-2277-4051-83C6-54DE5337E3CD Q36644129-1A648978-B3EA-4C8B-9FDE-A2597137C81F Q36725292-A7AB76D4-3C70-4A50-8012-7732773ADB48 Q36842189-7591294E-019A-4F1B-A4DF-5DC416055282 Q36856977-D06467E9-A1C6-4E98-A9BA-04D9ECEBFED0 Q36941752-736FB027-1929-413F-AE42-D64D190F1767 Q37016031-BE7B446C-79A7-4E45-B173-25A106EC92BC Q37086136-24AA5ADF-E6FC-4655-9505-0EDFF6012350 Q37129378-8B0D1828-8196-414C-BF5D-E51BD8CE999F Q37131229-EC24D4F2-761B-4039-B991-1A7840595901

P2860

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

http://www.wikidata.org/entity/Q34649706

description

2004 nî lūn-bûn

@nan

2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Pramipexole vs levodopa as ini ...... r randomized controlled trial.

@ast

Pramipexole vs levodopa as ini ...... r randomized controlled trial.

@en

Pramipexole vs levodopa as ini ...... r randomized controlled trial.

@en-gb

Pramipexole vs levodopa as ini ...... r randomized controlled trial.

@nl

type

label

Pramipexole vs levodopa as ini ...... r randomized controlled trial.

@ast

Pramipexole vs levodopa as ini ...... r randomized controlled trial.

@en

Pramipexole vs levodopa as ini ...... r randomized controlled trial.

@en-gb

Pramipexole vs levodopa as ini ...... r randomized controlled trial.

@nl

prefLabel

Pramipexole vs levodopa as ini ...... r randomized controlled trial.

@ast

Pramipexole vs levodopa as ini ...... r randomized controlled trial.

@en

Pramipexole vs levodopa as ini ...... r randomized controlled trial.

@en-gb

Pramipexole vs levodopa as ini ...... r randomized controlled trial.

@nl

P1433

Q34649706-1EA72643-5E43-49E5-9188-213C579B8494

P1476

Q34649706-131D848D-750A-47A7-9DC9-0475D0EEEC18

P2093

Q34649706-03C31560-1BDA-4CE5-9E4E-945BC83D79D4

Q34649706-04F9AB74-349B-4031-9C99-2F1753F7E584

Q34649706-0A68DF4F-FDE6-4029-A243-02084DD55DAE

Q34649706-0F043386-7A54-47F9-AA3B-91C6C2347E0D

Q34649706-0F4B3E6F-E7E7-4558-B9BD-53E170996BFA

Q34649706-186805DF-DF14-4A63-BC95-694C3173A4D0

Q34649706-1BEC1842-D39B-4D60-BC35-40DA899DE8E1

Q34649706-1C07325B-4701-4728-AF87-682867B1ED72

Q34649706-20CF7E01-D435-44A7-9960-AE7D0C563446

Q34649706-244BD520-699B-4D78-869C-BFDD1D98E60A

P304

Q34649706-62CF0CFE-F0DD-4907-9451-B905E3B74305

P31

Q34649706-56F8CC65-AEE9-4F1A-B061-7B87446B20B3

P356

Q34649706-087D7560-0715-4445-956F-E5FDEB727F30

P433

Q34649706-D715DE1D-2AF4-4891-8CBF-4D1242E09423

P478

Q34649706-3ADE0851-1126-45EF-8CEF-3784E163D936

P50

Q34649706-66C68C72-AA07-4445-98FC-2B09E76E0EB2

Q34649706-92F6A4BB-7368-4079-A0D6-B2C5D2EBE22D

Q34649706-9EFA9B61-6494-4185-A741-9C449EA8A08C

Q34649706-BAEC7675-05FF-4F9B-9828-645E437CF659

Q34649706-BD747E9C-3BCA-4F1A-BB6D-06C66AE87689

Q34649706-D65D3EF6-12FD-4368-B018-271ACB1C8689

Q34649706-FEC1C704-0CBA-4082-9B84-305B699484C5

P577

Q34649706-4AD58784-3C89-4163-AD11-09F1369957C2

P698

Q34649706-0E0A1C5A-3510-43EE-B22A-50F5A41F02FA

P921

Q34649706-BC96F60F-E068-4B4F-A772-75EC38E6818B

Q34649706-D56EC1D9-04CE-4F10-B4D4-74ADCB249CAF

P356

ARCHNEUR.61.7.1044

P1433

P1476

Pramipexole vs levodopa as ini ...... r randomized controlled trial.

@en

P2093

Aileen Shinaman

http://www.w3.org/2001/XMLSchema#string

Ali Rajput

http://www.w3.org/2001/XMLSchema#string

Alicia Brocht

http://www.w3.org/2001/XMLSchema#string

Amy Montgomery

http://www.w3.org/2001/XMLSchema#string

Arthur Watts

http://www.w3.org/2001/XMLSchema#string

Barbara Alexander-Brown

http://www.w3.org/2001/XMLSchema#string

Barbara Fussell

http://www.w3.org/2001/XMLSchema#string

Blair Ford

http://www.w3.org/2001/XMLSchema#string

Brenda Pfeiffer

http://www.w3.org/2001/XMLSchema#string

Bruno Musch

http://www.w3.org/2001/XMLSchema#string

P304

1044-1053

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHNEUR.61.7.1044

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

Michael McDermott

Joseph Jankovic

Stewart A Factor

P577

2004-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15262734

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease